# US 2006/0134116 A1 · Ca 125 tumor antigen function and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2006/0134116 A1 - Document ID: US20060134116A1 - Status: Published application - Kind: A1 - Application number: 10/507,728 - Filed: 2003-03-11 - Published: 2006-06-22 - Earliest claimed: 2002-03-11 - Assignees: Universite de Sherbrooke - Inventors: Claudine Rancourt; Alain Piche; Julie Beaudin - Web page: https://patentgrep.com/patent/US20060134116A1 ## CPC - C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate} - A61P 35/00: Antineoplastic agents - A61K 2039/505: {comprising antibodies} - C07K 2317/622: Single chain antibody (scFv) - C07K 2319/02: containing a signal sequence - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention is directed to modulators of CA 125 tumor antigen, a recombinant nucleic acids, vectors, host cells, pharmaceutical compositions, uses of the foregeoing for negatively modulating CA 125 tumor antigen in mammalian cell, preventing and treating a CA 125 tumor antigen associated disease in a mammal, as well as methods of prevention and treatment of such diseases and methods of negatively regulating CA 125 tumor antigen in a mammalian cell. ## Claims ### Claim 1 A modulator capable of negatively modulating a CA 125 tumor antigen in a mammalian cell. ### Claim 2 (depends on 1) The modulator according to claim 1, wherein it negatively modulates cell surface expression of CA 125 tumor antigen. ### Claim 3 (depends on 1, 2) The modulator according to claim 1 or 2, wherein it sequesters CA 125 tumor antigen or a fragment thereof within an organelle of a mammalian cell. ### Claim 4 (depends on 3) The modulator according to claim 3, wherein the organelle is selected from the group consisting of the endoplasmic reticulum, the trans-golgi, the golgi, the mitochondrion, the cytoplasm and a cellular compartment. ### Claim 5 (depends on 1, 2, 3, 4) The modulator according to any one of claims 1 to 4, wherein it is a single-chain antibody that specifically binds to CA 125 tumor antigen or a fragment thereof. ### Claim 6 (depends on 5) The modulator according to claim 5, wherein the single-chain antibody is derived from the group consisting of OC 125 monoclonal antibody and VK-8 monoclonal antibody. ### Claim 7 (depends on 5, 6) The modulator according to claim 5 or 6, wherein the single-chain antibody comprises a fragment coded by at least one sequence of the group consisting of SEQ. ID NOS 1 to 6. ### Claim 8 (depends on 7) The modulator according to claim 7, wherein the single-chain antibody is coded by a sequence selected from the group consisting of SEQ. ID NOS 1 and 2. ### Claim 9 A recombinant nucleic acid comprising at least one sequence selected from the group consisting of SEQ ID NOS 1 to 6. ### Claim 10 (depends on 10) A vector comprising a recombinant nucleic acid according to claim 10. ### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) A host cell comprising at least one element selected from the group consisting of: a modulator according to any one of claims 1 to 8; a recombinant nucleic acid according to claim 9; and a vector according to claim 10. ### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one element selected from the group consisting of: a modulator according to any one of claims 1 to 8; a recombinant nucleic acid according to claim 9; a vector according to claim 10; and a host cell according to claim 11. ### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) Use of at least one element selected from the group consisting of: a modulator according to any one of claims 1 to 8; a recombinant nucleic acid according to claim 9; and a vector according to claim 10; for negatively modulating a CA 125 tumor antigen in a mammalian cell. ### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) Use of at least one element selected from the group consisting of: a modulator according to any one of claims 1 to 8; a recombinant nucleic acid according to claim 9; a vector according to claim 10; a host cell according to claim 11; and a pharmaceutical composition according to claim 12; for preventing and treating a CA 125-tumor-antigen-associated disease in a mammal. ### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) A method of prevention or treatment of a CA 125-tumor-antigen-associated disease in a mammal comprising the step of administrating to said mammal at least one element selected from the group consisting of: a modulator according to any one of claims 1 to 9; a recombinant nucleic acid according to claim 10; a vector according to claim 11; and a host cell according to claim 12. ### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11) A method for negatively modulating a CA 125 tumor antigen in a mammalian cell comprising the step of introducing into said cell at least one element selected from the group consisting of: a modulator according to any one of claims 1 to 9; a recombinant nucleic acid according to claim 10; and a vector according to claim 11.